The Presage ST2 immunoassay from Critical Diagnostics, San Diego, can detect the cardiac biomarker ST2 and help differentiate hypertensive heart failure (HHF) patients from those with hypertension (HT) with or without left ventricular hypertrophy (LVH), according to a new study published in Journal of Human Hypertension. “The Effect of Left Ventricle Remodelling on Soluble ST2 in a Cohort of Hypertensive Subjects” also showed that ST2 was useful in distinguishing hypertensive LVH from hypertension without LVH. The results can help guide treatment decisions, since patients with hypertension are more likely to develop LVH and eventual heart disease. ST2 is a soluble protein expressed by the heart in response to disease or injury. Since it changes rapidly according to variations in a patient’s condition and is unaffected by factors such as age or body mass index, the biomarker is suitable for assessing heart failure patients. For more information and to view the full press release, visit Critical Diagnostics.
